Status:
RECRUITING
Treatment of Supine Hypertension in Autonomic Failure (CPAP)
Lead Sponsor:
Vanderbilt University Medical Center
Conditions:
Supine Hypertension
Autonomic Failure
Eligibility:
All Genders
18-85 years
Phase:
NA
Brief Summary
Supine hypertension is a common problem that affects at least 50% of patients with primary autonomic failure. Supine hypertension can be severe and complicates the treatment of orthostatic hypotension...
Detailed Description
Supine hypertension is a common problem that affects at least 50% of patients with primary autonomic failure. Supine hypertension can be severe and complicates the treatment of orthostatic hypotension...
Eligibility Criteria
Inclusion
- Patients with autonomic failure and with supine hypertension from all races
Exclusion
- All medical students
- Pregnant women
- High-risk patients (e.g. heart failure, symptomatic coronary artery disease, liver impairment, history of stroke or myocardial infarction)
- History of serious allergies or asthma.
Key Trial Info
Start Date :
September 21 2017
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 21 2026
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT03312556
Start Date
September 21 2017
End Date
December 21 2026
Last Update
November 6 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Autonomic Dysfunction Center/ Vanderbilt University Medical Center
Nashville, Tennessee, United States, 37232